2020 Health for Humanity Report Progress in Sustainability Contents | Message from Our CEO | Our Approach | United in Defeating COVID-19 | Better Health for All | Responsible Business Practices | Reporting Hub Contents Message from Our Chairman and CEO 3 2020 Year in Brief 4 Our Recognitions 5 Our Approach 6 Health for Humanity Strategy & Goals 9 Sustainability Governance 13 Sustainability Priorities 14 United in Defeating COVID-19 15 Caring for Patients 17 Supporting the Front Lines of Care 24 Protecting Employees 25 Supply Chain Resilience 28 Better Health for All 30 Innovation 31 Global Public Health Strategy 35 Access & Affordability 45 Strengthening Health Systems 48 Responsible Business Practices 52 Ethics & Values 53 Our People 60 Product Quality & Safety 74 Environmental Health 79 Responsible Supply Base 90 ABOVE: During the COVID-19 pandemic, Report overview community healthcare workers in Peru Reporting Hub 98 This Report details the progress of the Johnson & Johnson Family traveled door-to-door to reach children with ESG Summary 98 of Companies in sustainability. It is also our primary source of VERMOX Chewable tablets for treatment of Performance Data 98 annual disclosure on environmental, social and governance intestinal worms. The medicine is donated GRI Content Index 98 (ESG) performance and should be reviewed in conjunction by Johnson & Johnson and implemented GRI Culture of Health for Business Framework 98 with disclosures on the ESG Policies & Positions page. Data by INMED Partnerships for Children. SASB Index 98 in this Report cover the period between January 1, 2020, and Photo by INMED Partnerships for Children. TCFD 98 December 31, 2020, unless otherwise noted. Reporting on other FRONT COVER: Jacquelyn W., Senior UNGC Communication on Progress 98 matters specific to financial performance of the Company and its Warehouse Operator, celebrating the CDP Reports 98 subsidiaries can be found in our 2020 Annual Report. For more first outbound shipment of the Johnson & About this Report 99 information and the Cautionary Note Regarding Forward-Looking Johnson COVID-19 vaccine. Independent Assurance Statements 101 Statements, please see About this Report. Glossary 115 To read this report online, visit healthforhumanityreport.jnj.com. References 116 2020 Health for Humanity Report Contents | Message from Our CEO | Our Approach | United in Defeating COVID-19 | Better Health for All | Responsible Business Practices | Reporting Hub Message from Our Chairman and CEO GRI 102-14 To Our Global Community: chains, and launching a first-of-its-kind medical device ecosystem to take on the challenges of tomorrow. for the management of persistent atrial fibrillation. And, as always, we will hold ourselves to a high level We all know from firsthand experience that 2020 Delivering on our responsibilities to a healthy planet, of transparency and accountability through reports was a year of profound upheaval and uncertainty. we made progress on reducing our carbon footprint, such as this one and our annual Janssen U.S. It was also, however, a clarifying moment for us at including achieving more than 50% use of renewable Transparency Report. Johnson & Johnson. electricity globally. As we grappled with the wide-ranging impacts of Throughout 2020, bearing witness to the way the the COVID-19 pandemic and the ongoing economic pandemic revealed weaknesses in our public health volatility that threw into stark relief the issues of racial systems and pushed businesses to do more to create injustice and health inequities, one thing was certain: healthier, more equitable communities was sometimes a when it comes to global public health, the stakes could humbling experience—but it was also an inspiration. not be higher. While solving the most pressing global health challenges is never easy, the once-in-a-generation I’m pleased to be able to say that these challenges of confluence of these crises underscored the complexity 2020 only enhanced our commitment to—and continued that organizations like ours must navigate if we truly focus on—creating long-term value for all stakeholders want to make the maximum positive impact on human by integrating social considerations, environmental Alex Gorsky connecting with employees during a virtual visit health. sustainability and good governance into every aspect to our Shanghai and Beijing offices. of our business. From launching the Our Race to At Johnson & Johnson, taking on even the most Health Equity platform to address the root causes of I know we will continue to do our part through daunting healthcare challenges has been at the core healthcare inequity in the United States, to deepening whatever unknowable new challenges and upheavals of who we are for 135 years. And while living up to our commitments to address complex issues like lie ahead, because we will always be able to draw our commitments embodied in Our Credo has always smoking cessation, to environmental health innovations upon our ultimate strength: the remarkable people required constant evolution and innovation, the last year to make our packaging easier to recycle or reuse through of Johnson & Johnson. In an extraordinary year, our demanded that we embrace radically new ways of doing the Healthy Lives initiative from Johnson & Johnson 136,000-plus global employees embraced radically business and even greater heights of purpose-driven Consumer Health, we have kept our sights firmly set on new ways of working with greater agility than ever collaboration through public–private partnerships. catalyzing lasting change. before. Each individual’s ingenuity and resilience are As we detail in this Report, the significant challenges of what allowed us to go above and beyond for all our To help lead the world into a brighter post-COVID-19 2020 did not deter us from accomplishing many of our stakeholders. I could not be prouder of what Johnson & future where healthier families flourish in healthier key goals. Johnson employees showed the world is possible— societies on a healthier planet, we know we must or more optimistic about what their passion and While much of the world’s attention was on our capitalize on the incredible momentum we’ve unleashed perseverance will help us achieve in the future. leadership in the fight against theCOVID-19 at Johnson & Johnson this past year. pandemic—culminating in the deployment of our Building on our Health for Humanity 2020 Goals—the Janssen COVID-19 vaccine this year—we also achieved successes and shortcomings of which are detailed in this our Health for Humanity 2020 Goals of fighting HIV and Report—we are launching even more ambitious goals tuberculosis, as well as accelerating broader access to for 2025 that will enable us to continue living into Our our Ebola vaccine for those most in need. We brought Purpose as we make further contributions to 11 of the 17 this same agility to our work on behalf of our patients United Nations 2030 Sustainable Development Goals. and customers in areas as diverse as advancing the Given how essential collaboration was to our shared Alex Gorsky science around the treatment of multiple myeloma, progress in 2020, we’re actively expanding on many of Chairman, Board of Directors deploying technological innovations and application of our historic partnerships across the entire healthcare and Chief Executive Officer data science to safeguard critically important supply 2020 Health for Humanity Report 3 Contents | Message from Our CEO | Our Approach | United in Defeating COVID-19 | Better Health for All | Responsible Business Practices | Reporting Hub 2020 Year in Brief OUR NEW COMMITMENTS AND GOALS $100 million $800 million ambitious Health for Humanity 2025 Goals committed over the next five years in the U.S. to help committed through 2030 to advance our Healthy addressing pandemics and epidemics, global health eliminate health inequities for people of color Lives Mission, to make our Consumer Health equity, our people, planet and partners products more sustainable 21 OUR IMPACT People We Serve Combating COVID-19 Advancing Breakthrough Science for HIV Preventing Future Ebola Within a year, began manufacturing our single-shot Received European Commission Marketing Outbreaks COVID-19 vaccine, now authorized for emergency Authorization for REKAMBYS (rilpivirine injection) to Received European Commission use by the U.S. FDA, granted a Conditional Marketing be used with ViiV Healthcare’s Vocabria (cabotegravir Marketing Authorization for 11 Authorization by the European Commission, and injection) as the first-ever complete, long-acting Photo by Rwanda Ebola vaccine regime for the issued an Emergency Use Listing by the World Health injectable HIV treatment regimen Ministry of Health. prevention of Ebola Virus Disease Organization (WHO) Treating Atrial Fibrillation Partnering to Stop Smoking Expanding Access to MDR-TB Treatment Received CE mark approval for QDOT MICRO As part of the Access Initiative for Quitting Tobacco, Collaborated with the Stop TB Partnership’s Global Catheter, next-generation high-power, short-duration launched by the WHO to reduce smoking rates around Drug Facility to develop and implement a novel access ablation catheter for the treatment of atrial fibrillation the world, Johnson & Johnson Consumer Health framework for SIRTURO (bedaquiline) for 135+ low- donated nicotine replacement therapy patches and middle-income countries Employees Communities & Planet Shareholders Over 100 46% $2.6 billion 54% of our $12.2 billion medically trained employees of management